{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:25:54Z","timestamp":1792092354819,"version":"4.4.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The surgical management of breast cancer has achieved considerable improvement, shifting from radical resections toward increasingly conservative approaches driven by the advances in systemic therapy, precision imaging, and tumor biology. De-escalation strategies reducing the extent of surgery in the breast and axilla, aiming to minimize treatment-related morbidity (e.g., lymphedema, chronic pain, impaired mobility), while maintaining oncologic safety. This review synthesizes evidence from over 20 landmark trials, critically examines current clinical guidelines, and explores emerging technologies (e.g., artificial intelligence, liquid biopsy) that may further refine patient selection. We also highlight global disparities in adopting de-escalation strategies and discuss unanswered questions, such as applicability in high-risk subtypes and long-term recurrence risks.<\/jats:p>","DOI":"10.3389\/fonc.2026.1717340","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:10Z","timestamp":1771910350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["De-escalating breast and axillary surgery in breast cancer: evidence, controversies, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Baha","family":"Sharaf","sequence":"first","affiliation":[{"name":"Department of Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala\u2019","family":"Seif","sequence":"additional","affiliation":[{"name":"Department of Surgery, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Alawneh","sequence":"additional","affiliation":[{"name":"Department of Surgery, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Bani Hani","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Sh Abrahim","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif","family":"Jehad","sequence":"additional","affiliation":[{"name":"School of Medicine, Yarmouk University","place":["Irbid, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Hussein Cancer Center","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleiman","family":"Mahafdah","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jordanian Royal Medical Services","place":["Amman, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00000658-189407000-00075","article-title":"The results of operations for cure of cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894","volume":"20","author":"Halsted","year":"1894","journal-title":"Ann Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.98","article-title":"A historical account of breast cancer surgery: beware of local recurrence but be not radical","volume":"10","author":"Halsted","year":"2014","journal-title":"Future Oncol"},{"key":"B3","first-page":"1","article-title":"Consensus statement: treatment of early-stage breast cancer","year":"1992","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2354.2009.01020.x","article-title":"Breast cancer surgery: a historical narrative. Part II. 18th and 19th centuries","volume":"19","author":"Sakorafas","year":"2010","journal-title":"Eur J Cancer Care (Engl)"},{"key":"B5","article-title":"Evolution of radical mastectomy for breast cancer","volume":"9","author":"Plesca","year":"2016","journal-title":"J Med Life"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/bjc.1948.2","article-title":"The prognosis of carcinoma of the breast in relation to the type of operation performed","volume":"2","author":"Patey","year":"1948","journal-title":"Br J Cancer"},{"key":"B7","article-title":"Modified radical mastectomy","volume":"121","author":"Madden","year":"1965","journal-title":"Surg Gynecol Obstet"},{"key":"B8","article-title":"Laboratory and clinical research in breast cancer\u2014a personal adventure: the David A","volume":"40","author":"Fisher","year":"1980","journal-title":"Karnofsky memorial lecture. Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10741","article-title":"Pathobiology of preoperative chemotherapy","volume":"95","author":"Fisher","year":"2002","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4359-5","article-title":"From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer","volume":"165","author":"Abdel-Razeq","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B11","first-page":"15","article-title":"Conservation therapy of operable breast cancer: results at 5, 10, and 15 years in 2216 consecutive cases","volume-title":"Conservative Management of Breast Cancer","author":"Amalric","year":"1983"},{"key":"B12","first-page":"3","article-title":"Conservative treatment of operable breast carcinoma by irradiation with or without limited surgery: ten years results","volume-title":"Conservative Management of Breast Cancer","author":"Calle","year":"1983"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(85)90203-7","article-title":"Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency, and salvage","volume":"11","author":"Recht","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","article-title":"Conservative surgery and irradiation in clinically favorable breast cancer: the MD Anderson experience","volume-title":"Conservative Management of Breast Cancer","author":"Montague","year":"1983"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1558","article-title":"Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group","volume":"14","author":"Arriagada","year":"1996","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(86)90027-1","article-title":"Local control and survival in early breast cancer: the Milan trial","volume":"12","author":"Veronesi","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS4-01","article-title":"Abstract GS4-01: impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer\u2014results from ACOSOG Z11102 (Alliance)","volume":"83","author":"Boughey","year":"2023","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02553","article-title":"Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance)","volume":"41","author":"Boughey","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08893-w","article-title":"Cosmetic outcomes following breast-conservation surgery and radiation for multiple ipsilateral breast cancer: data from the Alliance Z11102 study","volume":"27","author":"Rosenkranz","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B21","article-title":"Conservative treatment of multifocal breast cancer: a comparative study","volume":"86","author":"Nos","year":"1999","journal-title":"Bull Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(03)00528-7","article-title":"Breast conservation in patients with multiple ipsilateral synchronous cancers","volume":"197","author":"Kaplan","year":"2003","journal-title":"J Am Coll Surg"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4578","article-title":"Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy","volume":"24","author":"Oh","year":"2006","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9950-8","article-title":"Conservative surgery in patients with multifocal\/multicentric breast cancer","volume":"113","author":"Gentilini","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0184","article-title":"Breast cancer multifocality and multicentricity and locoregional recurrence","volume":"18","author":"Lynch","year":"2013","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2760-0","article-title":"Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8935 patients","volume":"142","author":"Wolters","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/bjs5.64","article-title":"Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers","volume":"2","author":"Winters","year":"2018","journal-title":"BJS Open"},{"key":"B28","unstructured":"ClinicalTrials.gov\n          MIAMI safe surgery for multiple breast cancers (ClinicalTrials.gov identifier NCT03514654)\n          \n          2023"},{"key":"B29","unstructured":"Omission of breast surgery in exceptional responders after neoadjuvant chemotherapy\u2014what are future possibilities?\u2014a narrative review\n          \n          65\n          \n            \n              Meyers\n              AK\n            \n            \n              Al-Saffar\n              F\n            \n            \n              Saffari\n              AM\n            \n            \n              Wei\n              S\n            \n            \n              Strawderman\n              MS\n            \n            \n              Zhang\n              S\n            \n          \n          10.21037\/tbcr-24-65\n          40421157\n          Transl Breast Cancer Res\n          5\n          2024"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09273-0","article-title":"Minimally invasive complete response assessment of the breast after neoadjuvant systemic therapy for early breast cancer (MICRA trial): interim analysis of a multicenter observational cohort study","volume":"28","author":"van","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/2023.03.06.23286772","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","author":"Parsons","year":"2023","journal-title":"medRxiv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2025.1072","article-title":"Breast tumor-Bed biopsy for pathological complete response prediction: the NRG-BR005 nonrandomized clinical trial","volume":"160","author":"Basik","year":"2025","journal-title":"JAMA Surgery"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS613","article-title":"A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008","volume":"42","author":"Braunstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cncr.21568","article-title":"Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma","volume":"106","author":"Kim","year":"2006","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.1000","article-title":"Ten-year follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection with conventional axillary dissection in clinically node-negative breast cancer patients","volume":"31","author":"Julian","year":"2013","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znad391","article-title":"Lessons from the SOUND trial and future perspectives on axillary staging in breast cancer","volume":"111","author":"Gentilini","year":"2024","journal-title":"Br J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer: primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2414899","article-title":"Sentinel-lymph-node biopsy in early-stage breast cancer\u2014is it obsolete","volume":"392","author":"Morrow","year":"2025","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12885-022-09273-1","article-title":"No axillary surgical treatment for lymph node-negative patients after ultrasonography (NAUTILUS): protocol of a prospective randomized clinical trial","volume":"22","author":"Jung","year":"2022","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA1","article-title":"TAILORx: phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor\u2013positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score","volume":"36","author":"Sparano","year":"2018","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","article-title":"Clinically node-negative breast cancer patients undergoing breast-conserving therapy: sentinel lymph node procedure versus follow-up (BOOG 2013-08)","volume":"17","author":"van","year":"2017","journal-title":"BMC Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2022.0085","article-title":"Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial","volume":"19","author":"Li","year":"2022","journal-title":"Cancer Biol Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2003.03.015","article-title":"A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy","volume":"10","author":"Van","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981\u201322023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00627-1","article-title":"First, do no harm: risk of secondary cancer after breast cancer treatment","volume":"23","author":"Rugo","year":"2022","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"11631175","DOI":"10.1056\/NEJMoa2313487","article-title":"et al. Omitting axillary dissection in breast cancer with sentinel-Node metastases","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2015.07.005","article-title":"POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases","volume":"27","author":"Goyal","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B53","unstructured":"A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1\u20133 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy\n          \n          \n          ClinicalTrials.gov"},{"key":"B54","doi-asserted-by":"publisher","first-page":"173182","DOI":"10.1016\/j.breast.2023.03.005","article-title":"Tailored axillary surgery \u2013 A novel concept for clinically node-positive breast cancer: the OPBC-03\/TAXIS trial","volume":"70","author":"Heidinger","year":"2023","journal-title":"The Breast"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11866-w","article-title":"Preservation of axillary lymph nodes compared with complete dissection in T1\u20132 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial","volume":"29","author":"Tinterri","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100496","article-title":"NEONOD 2: rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy","volume":"17","author":"Tinterri","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.003","article-title":"KEYNOTE-522: phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)","volume":"30","author":"Schmid","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1717340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:14Z","timestamp":1771910354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1717340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":57,"alternative-id":["10.3389\/fonc.2026.1717340"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1717340","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1717340"}}